QQQ   354.90 (+0.82%)
AAPL   180.98 (+0.49%)
MSFT   334.84 (+0.68%)
META   273.48 (+0.32%)
GOOGL   125.07 (+1.09%)
AMZN   125.09 (+1.89%)
TSLA   216.60 (+4.38%)
NVDA   396.05 (-0.41%)
NIO   7.64 (+1.33%)
BABA   85.05 (+2.47%)
AMD   119.42 (-0.04%)
T   15.07 (-4.68%)
F   12.44 (+2.73%)
MU   68.96 (-0.19%)
CGC   0.84 (+0.63%)
GE   106.37 (+1.62%)
DIS   90.68 (+2.36%)
AMC   4.55 (+0.00%)
PFE   38.46 (+1.16%)
PYPL   64.18 (+1.79%)
NFLX   404.54 (+0.35%)
QQQ   354.90 (+0.82%)
AAPL   180.98 (+0.49%)
MSFT   334.84 (+0.68%)
META   273.48 (+0.32%)
GOOGL   125.07 (+1.09%)
AMZN   125.09 (+1.89%)
TSLA   216.60 (+4.38%)
NVDA   396.05 (-0.41%)
NIO   7.64 (+1.33%)
BABA   85.05 (+2.47%)
AMD   119.42 (-0.04%)
T   15.07 (-4.68%)
F   12.44 (+2.73%)
MU   68.96 (-0.19%)
CGC   0.84 (+0.63%)
GE   106.37 (+1.62%)
DIS   90.68 (+2.36%)
AMC   4.55 (+0.00%)
PFE   38.46 (+1.16%)
PYPL   64.18 (+1.79%)
NFLX   404.54 (+0.35%)
QQQ   354.90 (+0.82%)
AAPL   180.98 (+0.49%)
MSFT   334.84 (+0.68%)
META   273.48 (+0.32%)
GOOGL   125.07 (+1.09%)
AMZN   125.09 (+1.89%)
TSLA   216.60 (+4.38%)
NVDA   396.05 (-0.41%)
NIO   7.64 (+1.33%)
BABA   85.05 (+2.47%)
AMD   119.42 (-0.04%)
T   15.07 (-4.68%)
F   12.44 (+2.73%)
MU   68.96 (-0.19%)
CGC   0.84 (+0.63%)
GE   106.37 (+1.62%)
DIS   90.68 (+2.36%)
AMC   4.55 (+0.00%)
PFE   38.46 (+1.16%)
PYPL   64.18 (+1.79%)
NFLX   404.54 (+0.35%)
QQQ   354.90 (+0.82%)
AAPL   180.98 (+0.49%)
MSFT   334.84 (+0.68%)
META   273.48 (+0.32%)
GOOGL   125.07 (+1.09%)
AMZN   125.09 (+1.89%)
TSLA   216.60 (+4.38%)
NVDA   396.05 (-0.41%)
NIO   7.64 (+1.33%)
BABA   85.05 (+2.47%)
AMD   119.42 (-0.04%)
T   15.07 (-4.68%)
F   12.44 (+2.73%)
MU   68.96 (-0.19%)
CGC   0.84 (+0.63%)
GE   106.37 (+1.62%)
DIS   90.68 (+2.36%)
AMC   4.55 (+0.00%)
PFE   38.46 (+1.16%)
PYPL   64.18 (+1.79%)
NFLX   404.54 (+0.35%)
NYSE:EBS

Emergent BioSolutions (EBS) Stock Forecast, Price & News

$8.25
+0.05 (+0.61%)
(As of 11:57 AM ET)
Compare
Today's Range
$8.16
$8.45
50-Day Range
$8.10
$13.21
52-Week Range
$7.74
$36.14
Volume
347,227 shs
Average Volume
1.49 million shs
Market Capitalization
$416.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.00

Emergent BioSolutions MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
242.3% Upside
$28.00 Price Target
Short Interest
Healthy
14.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.40
Upright™ Environmental Score
News Sentiment
0.11mentions of Emergent BioSolutions in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.41) to $0.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

507th out of 1,980 stocks

Pharmaceutical Preparations Industry

225th out of 978 stocks


EBS stock logo

About Emergent BioSolutions (NYSE:EBS) Stock

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

What 4 Analyst Ratings Have To Say About Emergent BioSolutions
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
8-K: Emergent BioSolutions Inc.
See More Headlines

EBS Price History

EBS Company Calendar

Last Earnings
5/09/2023
Today
6/02/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
CUSIP
29089Q10
Employees
2,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.00
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+242.3%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-223,800,000.00
Pretax Margin
-38.73%

Debt

Sales & Book Value

Annual Sales
$1.12 billion
Cash Flow
$0.71 per share
Book Value
$23.84 per share

Miscellaneous

Free Float
49,489,000
Market Cap
$412.68 million
Optionable
Optionable
Beta
0.93

Key Executives

  • Robert G. Kramer
    President, Chief Executive Officer & Director
  • Adam Robert Havey
    Chief Operating Officer & EVP-Business Operations
  • Richard Scott LindahlRichard Scott Lindahl
    Chief Financial Officer, Treasurer & Executive VP
  • Sharon M. Solomon
    Chief Information Officer & Senior Vice President
  • Kelly Warfield
    Senior Vice President-Science & Development













EBS Stock - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings
or view top-rated stocks.

What is Emergent BioSolutions' stock price forecast for 2023?

5 brokerages have issued 12 month price targets for Emergent BioSolutions' stock. Their EBS share price forecasts range from $9.00 to $55.00. On average, they predict the company's stock price to reach $28.00 in the next year. This suggests a possible upside of 242.3% from the stock's current price.
View analysts price targets for EBS
or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2023?

Emergent BioSolutions' stock was trading at $11.81 at the start of the year. Since then, EBS shares have decreased by 30.7% and is now trading at $8.18.
View the best growth stocks for 2023 here
.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 6,650,000 shares, a decrease of 7.5% from the April 15th total of 7,190,000 shares. Based on an average trading volume of 1,810,000 shares, the days-to-cover ratio is presently 3.7 days. Currently, 15.1% of the company's shares are sold short.
View Emergent BioSolutions' Short Interest
.

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our EBS earnings forecast
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($3.17) earnings per share for the quarter, missing analysts' consensus estimates of ($1.67) by $1.50. The biopharmaceutical company earned $165.10 million during the quarter, compared to analysts' expectations of $142.85 million. Emergent BioSolutions had a negative net margin of 41.20% and a negative trailing twelve-month return on equity of 20.18%. The firm's revenue was down 46.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.18 EPS.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.10 billion-$1.20 billion, compared to the consensus revenue estimate of $1.13 billion.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (18.37%), State Street Corp (10.72%), Dimensional Fund Advisors LP (3.59%), Hotchkis & Wiley Capital Management LLC (1.87%), Geode Capital Management LLC (1.78%) and Charles Schwab Investment Management Inc. (1.63%). Insiders that own company stock include Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends
.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $8.18.

How much money does Emergent BioSolutions make?

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $412.68 million and generates $1.12 billion in revenue each year. The biopharmaceutical company earns $-223,800,000.00 in net income (profit) each year or ($8.06) on an earnings per share basis.

How many employees does Emergent BioSolutions have?

The company employs 2,500 workers across the globe.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.

This page (NYSE:EBS) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -